Brief: BioArctic Says FDA Grants Priority Review To Leqembi Iqlik Supplemental Application
26/01/2026 02:48
Jan 25 (Reuters) - BioArctic AB BIOAb.ST: LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION REGARDING SUBCUTANEOUS STARTING DOSE GRANTED PRIORITY REVIEW BY THE US FDA BIOARCTIC AB - PDUFA ACTION DATE FOR LEQEMBI IQLIK SET FOR MAY 24, 2026 Source text: ID:nPnt0jT9a Further company coverage: [BIOAb.ST] ((Reuters.briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million